{
    "symbol": "CLGN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-29 12:28:03",
    "content": " With us on the call today from CollPlant are Yehiel Tal, Chief Executive Officer, who will provide an overview of the company's programs and forthcoming updates; and Eran Rotem, Chief Financial Officer, who will provide a summary of CollPlant's financial results for the full-year ending December 31, 2022. GAAP cost of revenue for the year ended December 31, 2022 was $400,000, a decrease of 80% compared to $2 million in the year 2021. GAAP gross loss for the year-ended December 31, 2022 was $101,000 compared to gross profit of $13.6 million in the year-ended December 31, 2021. GAAP operating expenses for the year ended December 31, 2022, was $17 million compared to $13.6 million in 2021. On a non-GAAP basis, the operating expenses for the year ended December 31st 2022 was $15.2 million compared to $11.9 million for the year ended December 31st 2021. GAAP net loss for the year ended December 31st 2022 was $16.9 million, or $1.53 basic loss per share compared to a net income of $237 or $0.02 income per share for year ended December 31, 2021. Or, $1.37 basic loss per share compared to $1.9 million income or $0.19 basic income per share for the year ended December 31st 2021. So, in closing, I want to reiterate our upcoming goals for 2023: continue to advance development of paradigm shifting regenerative, dermal and soft tissue fillers with AbbVie, expecting first milestone achievement in 2023, initiate study in large animals with commercial sized breast implants to generate additional safety data in support of commercialization, advanced development of the Gut-on-a-Chip tissue model for drug discovery and personalized treatment of ulcerative colitis."
}